Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Morgenstern

Showing results (31-40 of 179) with videos related to

Pageof 18
Sort By:
Scientific Reports|June 6, 2019
Assessment of <sup>213</sup>Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-<sup>13</sup>C]pyruvate and [<sup>18</sup>F]FDGBenedikt Feuerecker, Michael Michalik, Christian Hundshammer, et al.
Chemmedchem|July 3, 2020
First-Generation Bispidine Chelators for <sup>213</sup> Bi<sup>III</sup> Radiopharmaceutical ApplicationsFrank Bruchertseifer, Peter Comba, Bodo Martin, et al.
Scientific Reports|March 19, 2021
Diverse metabolic response of cancer cells treated with a <sup>213</sup>Bi-anti-EGFR-immunoconjugateBenedikt Feuerecker, Philipp Biechl, Christof Seidl, et al.
EJNMMI Research|August 10, 2018
Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeuticsJakub Šimeček, Petr Hermann, Christof Seidl, et al.
Nuclear Medicine and Biology|March 3, 2012
High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneumChristian Rauch, Christof Seidl, Martin Schlapschy, et al.
Nuclear Medicine and Biology|April 10, 2024
Development of <sup>225</sup>Ac/<sup>213</sup>Bi generator based on α-ZrP-PAN composite for targeted alpha therapyLukáš Ondrák, Kateřina Ondrák Fialová, Michal Sakmár, et al.
Materials (Basel, Switzerland)|September 9, 2023
α-Zirconium(IV) Phosphate: Static Study of <sup>225</sup>Ac Sorption in an Acidic Environment and Its Kinetic Sorption Study Using <sup>nat</sup>Eu as a Model System for <sup>225</sup>AcLukáš Ondrák, Kateřina Ondrák Fialová, Martin Vlk, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 24, 2017
Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in RadiotherapyAlexander Wurzer, Christof Seidl, Alfred Morgenstern, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 13, 2018
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup>Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor ControlClemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2023
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?Benedikt Feuerecker, Clemens Kratochwil, Hojjat Ahmadzadehfar, et al.
Pageof 18

Showing results (31-40 of 179) with videos related to

Sort By:
Pageof 18
Scientific Reports|June 6, 2019
Assessment of <sup>213</sup>Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-<sup>13</sup>C]pyruvate and [<sup>18</sup>F]FDGBenedikt Feuerecker, Michael Michalik, Christian Hundshammer, et al.
Chemmedchem|July 3, 2020
First-Generation Bispidine Chelators for <sup>213</sup> Bi<sup>III</sup> Radiopharmaceutical ApplicationsFrank Bruchertseifer, Peter Comba, Bodo Martin, et al.
Scientific Reports|March 19, 2021
Diverse metabolic response of cancer cells treated with a <sup>213</sup>Bi-anti-EGFR-immunoconjugateBenedikt Feuerecker, Philipp Biechl, Christof Seidl, et al.
EJNMMI Research|August 10, 2018
Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeuticsJakub Šimeček, Petr Hermann, Christof Seidl, et al.
Nuclear Medicine and Biology|March 3, 2012
High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneumChristian Rauch, Christof Seidl, Martin Schlapschy, et al.
Nuclear Medicine and Biology|April 10, 2024
Development of <sup>225</sup>Ac/<sup>213</sup>Bi generator based on α-ZrP-PAN composite for targeted alpha therapyLukáš Ondrák, Kateřina Ondrák Fialová, Michal Sakmár, et al.
Materials (Basel, Switzerland)|September 9, 2023
α-Zirconium(IV) Phosphate: Static Study of <sup>225</sup>Ac Sorption in an Acidic Environment and Its Kinetic Sorption Study Using <sup>nat</sup>Eu as a Model System for <sup>225</sup>AcLukáš Ondrák, Kateřina Ondrák Fialová, Martin Vlk, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 24, 2017
Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in RadiotherapyAlexander Wurzer, Christof Seidl, Alfred Morgenstern, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 13, 2018
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup>Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor ControlClemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2023
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?Benedikt Feuerecker, Clemens Kratochwil, Hojjat Ahmadzadehfar, et al.
Pageof 18